ResearcherUniversity of California Davis Medical CenterNo recent work listed
Mei‐Juan Tu
Matched on ORCID iD 0000-0002-5787-5081; OpenAlex author ID A5015797608. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers
Papers 3
- Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. Co-author DOI 10.1016/j.canlet.2018.10.038↗
- Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.tranon.2019.01.009↗
- MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. Co-author DOI 10.18632/oncotarget.9999↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Edward Jae-Hoon Kim · 3 shared papers, 2016–2019 · strength 0.27
- Paper Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. DOI 10.1016/j.tranon.2019.01.009↗
- Paper Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. DOI 10.1016/j.canlet.2018.10.038↗
- Paper MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. DOI 10.18632/oncotarget.9999↗
- Aiming Yu · 3 shared papers, 2016–2019 · strength 0.27
- Paper Novel Synergistic Combination of Mitotic Arrest and Promotion of Apoptosis for Treatment of Pancreatic Adenocarcinoma. DOI 10.1016/j.tranon.2019.01.009↗
- Paper Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. DOI 10.1016/j.canlet.2018.10.038↗
- Paper MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis. DOI 10.18632/oncotarget.9999↗
- Zhijian Duan · 1 shared paper, 2019 · strength 0.10
- Richard J. Bold · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.